Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.15
-$0.76-1.81%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 17.45M | 14.37M | 12.50M | 27.78M | 25.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.45M | 14.37M | 12.50M | 27.78M | 25.82M |
| Cost of Revenue | 51.91M | 47.81M | 46.24M | 43.82M | 43.58M |
| Gross Profit | -34.46M | -33.44M | -33.74M | -16.04M | -17.76M |
| SG&A Expenses | 108.70M | 80.33M | 62.00M | 52.10M | 44.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 160.61M | 128.14M | 108.24M | 95.92M | 88.53M |
| Operating Income | -143.16M | -113.77M | -95.74M | -68.14M | -62.71M |
| Income Before Tax | -135.89M | -107.59M | -90.96M | -65.28M | -62.10M |
| Income Tax Expenses | -- | 0.00 | -5.00K | -5.00K | -4.00K |
| Earnings from Continuing Operations | -135.89 | -107.59 | -90.95 | -65.27 | -62.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -135.89M | -107.59M | -90.95M | -65.27M | -62.09M |
| EBIT | -143.16M | -113.77M | -95.74M | -68.14M | -62.71M |
| EBITDA | -142.28M | -113.14M | -95.26M | -67.76M | -62.39M |
| EPS Basic | -4.64 | -3.84 | -3.40 | -2.47 | -2.57 |
| Normalized Basic EPS | -2.85 | -2.39 | -2.12 | -1.53 | -1.58 |
| EPS Diluted | -4.64 | -3.84 | -3.41 | -2.47 | -2.57 |
| Normalized Diluted EPS | -2.85 | -2.39 | -2.12 | -1.53 | -1.58 |
| Average Basic Shares Outstanding | 116.12M | 110.89M | 106.93M | 104.45M | 98.41M |
| Average Diluted Shares Outstanding | 116.12M | 110.89M | 106.93M | 104.45M | 98.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |